Who cares? Too many variables. How many shares are outstanding at the time. How long it takes for preliminary clinical data? What companies approach CUBT interested in taking the company out preemptively before solid data?
Does the company start trials on other ocular treatments beyond AMD?
Does CUBT use some capital to do something with the rabies drug to get a PRV? And sell that PRV.
Will the company get research done on their pediatric brain tumor treatment?
Answer all the above--and I will give you a few numbers.
BTW-- love your posts. Reminds me of the fast talking Fedex guy on the old tv ads.
Market Data 
Markets 
AI
